The Compound LE135 Is an Inhibitor of the Retinoic Acid $\beta$

The compound LE135 is an inhibitor of the retinoic acid receptor, and blocks signaling through this receptor. In a mouse model of inflammatory bowel disease (IBD) , inflammation in the gastrointestinal (GI) epithelium is significantly exacerbated if animals are treated with LE135. Analysis of the CD4 T cell subsets found in the GI epithelium of LE135-treated mice compared to controls with IBD would likely show:

A) Reduced numbers of CD4 T cells of all subsets in the LE135-treated mice
B) Increased numbers of TGF- $\beta$ and IL-10-producing CD4 cells in the LE135-treated mice
C) Reduced numbers of IL-17 and IL-22-producing CD4 cells in the LE135-treated mice
D) Reduced numbers of iT_regs in the LE135-treated mice
E) Increased numbers of naive CD4 T cells in the LE135-treated mice